title: [Preventing papillomavirus infectious and herpes zoster: new vaccines].
abstract: Two new vaccines have been recently licensed : a quadrivalent vaccine against Human papillomavirus infections (HPV) 6, 11, 16 and 18, recommended to children from 9 years old and to young adults under the age of 26 years, and a vaccine against herpes zoster for adults from 60 years old onwards. A bivalent vaccine against HPV 16 and 18 will be shortly available. HPV vaccines are composed of the L1 structural proteins of 2 or 4 HPV genotypes, produced by genetic engineering and self-assembled. These inert vaccines are devoid of genetic materials and mimic the viral particle (virus-like particle, VLP). They allow, as suggested by the 4.5 to 5 years follow-up, to prevent HPV infections and the onset of pre-cancerous lesions associated with genotypes contained within the vaccine. They represent a major overhang in the vaccinology field, and, as anti-hepatitis B vaccine, will probably be effective in cancer prevention. Their use must be associated with the continued detection of cervix cancer by smears and also with the prevention of other sexually transmitted diseases. The herpes zoster vaccine is a living attenuated vaccine produced from the OKA/Merck strain already used in the vaccine against varicella. Its safety is good among persons 50 years old and over and its efficiency on lowering herpes zoster incidence, on the burden of illness and on post-herpetic neuralgia has been demonstrated in persons over 60 years old.
authors: CIC de vaccinologie Cochin-Pasteur, Pôle de médecine interne, Hôpital Cochin 27, rue du Faubourg Saint-Jacques, 75014 Paris, France.
authors: Benjamin
authors: B
authors: Silbermann
authors: Odile
authors: O
authors: Launay
mesh_terms: D000293:Adolescent; D000328:Adult; D019433:Chickenpox Vaccine / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D005260:Female; D006562:Herpes Zoster / Q000453:epidemiology / Q000517:prevention & control*; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects; D017410:Practice Guidelines as Topic; D014611:Vaccination
chemical_list: D019433:Chickenpox Vaccine; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines